Nonoperating Income (Expense) in USD of Zynerba Pharmaceuticals, Inc. from 2014 to Q2 2023

Taxonomy & unit: us-gaap: USD
Description: The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary: Zynerba Pharmaceuticals, Inc. quarterly and annual Nonoperating Income (Expense) history and change rate from 2014 to Q2 2023.
Zynerba Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending 30 Jun 2023 was $360,142.
Zynerba Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending 30 Jun 2023 was $1,204,148.
Zynerba Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $215,734.
Zynerba Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was $538,634, a 174% decline from 2020.
Zynerba Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2020 was $725,711, a 47% decline from 2019.
Source SEC data: View on sec.gov

Nonoperating Income (Expense), Trailing 12 Months (USD)

Nonoperating Income (Expense), Quarterly (USD)

Nonoperating Income (Expense), YoY Quarterly Change (%)

Nonoperating Income (Expense), Annual (USD)

Nonoperating Income (Expense), YoY Annual Change (%)

Zynerba Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2023	$1,204,148	$360,142	+$1,044,378		01 Apr 2023	30 Jun 2023	10-Q	14 Aug 2023	2023	Q2
Q1 2023	$159,770	$357,332	-$55,964	-14%	01 Jan 2023	31 Mar 2023	10-Q	15 May 2023	2023	Q1
Q4 2022	$215,734	$669,947	+$648,576	+3035%	01 Oct 2022	31 Dec 2022	10-K	28 Mar 2023	2022	FY
Q3 2022	$432,842	$183,273	+$188,326	+51%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2022	2022	Q3
Q2 2022	$621,168	$684,236	-$572,651	-513%	01 Apr 2022	30 Jun 2022	10-Q	14 Aug 2023	2023	Q2
Q1 2022	$48,517	$413,296	+$490,117		01 Jan 2022	31 Mar 2022	10-Q	15 May 2023	2023	Q1
Q4 2021	$538,634	$21,371	-$550,445	-96%	01 Oct 2021	31 Dec 2021	10-K	28 Mar 2023	2022	FY
Q3 2021	$11,811	$371,599	-$554,847	-303%	01 Jul 2021	30 Sep 2021	10-Q	14 Nov 2022	2022	Q3
Q2 2021	$566,658	$111,585	-$1,620,699	-107%	01 Apr 2021	30 Jun 2021	10-Q	10 Aug 2022	2022	Q2
Q1 2021	$2,187,357	$76,821	+$1,461,646	+95%	01 Jan 2021	31 Mar 2021	10-Q	16 May 2022	2022	Q1
Q4 2020	$725,711	$571,816	-$129,357	-18%	01 Oct 2020	31 Dec 2020	10-K	10 Mar 2021	2020	FY
Q3 2020	$855,068	$183,248	+$203,420		01 Jul 2020	30 Sep 2020	10-Q	15 Nov 2021	2021	Q3
Q2 2020	$651,648	$1,509,114	+$1,133,240	+301%	01 Apr 2020	30 Jun 2020	10-Q	09 Aug 2021	2021	Q2
Q1 2020	$481,592	$1,538,467	-$1,857,819	-582%	01 Jan 2020	31 Mar 2020	10-Q	12 May 2021	2021	Q1
Q4 2019	$1,376,227	$701,173	+$445,210	+174%	01 Oct 2019	31 Dec 2019	10-K	10 Mar 2021	2020	FY
Q3 2019	$931,017	$20,172	-$198,489	-111%	01 Jul 2019	30 Sep 2019	10-K	10 Mar 2021	2020	FY
Q2 2019	$1,129,506	$375,874	+$413,301		01 Apr 2019	30 Jun 2019	10-K	10 Mar 2021	2020	FY
Q1 2019	$716,205	$319,352	+$229,550	+256%	01 Jan 2019	31 Mar 2019	10-K	10 Mar 2021	2020	FY
Q4 2018	$486,655	$255,963	+$170,058	+198%	01 Oct 2018	31 Dec 2018	10-K	10 Mar 2020	2019	FY
Q3 2018	$316,597	$178,317	-$60,081	-25%	01 Jul 2018	30 Sep 2018	10-K	10 Mar 2020	2019	FY
Q2 2018	$376,678	$37,427	-$79,602	-189%	01 Apr 2018	30 Jun 2018	10-K	10 Mar 2020	2019	FY
Q1 2018	$456,280	$89,802	-$354,425	-80%	01 Jan 2018	31 Mar 2018	10-K	10 Mar 2020	2019	FY
Q4 2017	$810,705	$85,905	+$297,901		01 Oct 2017	31 Dec 2017	10-K	11 Mar 2019	2018	FY
Q3 2017	$512,804	$238,398	+$221,921	+1347%	01 Jul 2017	30 Sep 2017	10-K	11 Mar 2019	2018	FY
Q2 2017	$290,883	$42,175	+$44,307		01 Apr 2017	30 Jun 2017	10-K	11 Mar 2019	2018	FY
Q1 2017	$246,576	$444,227	+$454,998		01 Jan 2017	31 Mar 2017	10-K	11 Mar 2019	2018	FY
Q4 2016	$208,422	$211,996			01 Oct 2016	31 Dec 2016	10-K	12 Mar 2018	2017	FY
Q3 2016		$16,477	+$14,905	+948%	01 Jul 2016	30 Sep 2016	10-K	12 Mar 2018	2017	FY
Q2 2016		$2,132			01 Apr 2016	30 Jun 2016	10-K	12 Mar 2018	2017	FY
Q1 2016		$10,771			01 Jan 2016	31 Mar 2016	10-K	12 Mar 2018	2017	FY
Q3 2015		$1,572			01 Jul 2015	30 Sep 2015	10-Q	14 Nov 2016	2016	Q3

Zynerba Pharmaceuticals, Inc. Annual Nonoperating Income (Expense) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2022	$215,734	+$754,368		01 Jan 2022	31 Dec 2022	10-K	28 Mar 2023	2022	FY
2021	$538,634	-$1,264,345	-174%	01 Jan 2021	31 Dec 2021	10-K	28 Mar 2023	2022	FY
2020	$725,711	-$650,516	-47%	01 Jan 2020	31 Dec 2020	10-K	28 Mar 2023	2022	FY
2019	$1,376,227	+$889,572	+183%	01 Jan 2019	31 Dec 2019	10-K	01 Mar 2022	2021	FY
2018	$486,655	-$324,050	-40%	01 Jan 2018	31 Dec 2018	10-K	10 Mar 2021	2020	FY
2017	$810,705	+$1,019,127		01 Jan 2017	31 Dec 2017	10-K	10 Mar 2020	2019	FY
2016	$208,422	-$215,774	-2935%	01 Jan 2016	31 Dec 2016	10-K	11 Mar 2019	2018	FY
2015	$7,352	+$9,196		01 Jan 2015	31 Dec 2015	10-K	12 Mar 2018	2017	FY
2014	$1,844			01 Jan 2014	31 Dec 2014	10-K	27 Mar 2017	2016	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.